Cognition Therapeutics INC 8-K filings

Cognition Therapeutics reported positive results from its Phase 2 SHINE trial, showing a significant slowing of cognitive decline in Alzheimer's patients, and provided a business update.

Cognition Therapeutics' CT1812 shows promising results in a Phase 2 trial, demonstrating a slowing of cognitive decline in patients with mild-to-moderate Alzheimer's disease.

Cognition Therapeutics held its annual meeting on June 7, 2024, where stockholders elected two Class III directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor for the 2024 fiscal year.

Cognition Therapeutics announced its first quarter 2024 financial results, highlighted by the completion of enrollment in the SHIMMER study and anticipation of topline results from the SHINE study.

Cognition Therapeutics announced its 2023 financial results, highlighted clinical trial progress, and secured additional funding to extend its cash runway through May 2025.

Cognition Therapeutics has entered into an underwriting agreement to sell 6,571,428 shares of its common stock at $1.75 per share, expecting net proceeds of approximately $10.4 million.

Cognition Therapeutics reports a preliminary net loss of approximately $25.6 million for 2023 and holds $29.9 million in cash and cash equivalents as of December 31, 2023.

Cognition Therapeutics has awarded performance-based restricted stock units to its CEO, CFO, and CMO, vesting upon achievement of clinical milestones.